Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HiHat trial in relapsing-remitting multiple sclerosis
2024-519700-28-01Phase 2Authorised
- Sponsor
- Region Uppsala
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of rituximab and cladribine in multiple sclerosis (MS) (2 arms), sponsored by Region Uppsala. Primary endpoint: Treatment-related serious adverse events. Planned start Sep 2026; status: authorised.
02
Drugs
rituximabcladribine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2024-519700-28-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519700-28-01.